

Synthesis of the ABC Core of *Daphniphyllum* Alkaloids with a [5–6–7] Azatricyclic Scaffold via Ring Expansion of Azabicyclic and Azatricyclic Building Blocks

Clàudia Marquès, David González-Lizana, Faïza Diaba,* and Josep Bonjoch*



Cite This: *J. Org. Chem.* 2024, 89, 10212–10222



Read Online


ACCESS |

Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: The [5–6–7] azatricyclic ABC core, found in several *Daphniphyllum* alkaloids, has been synthesized through a novel route involving ring expansion of a perhydroindolone to afford the AC ring system and a radical B ring closure as key steps. The level of functionalization of the reported octahydro-1,7-ethanocyclohepta[*b*]pyrroles suggests that they can serve as valuable building blocks in this alkaloid field. Also reported is the first synthesis of homomorphans by the ring enlargement of 2-azabicyclo[3.3.1]nonanes.



INTRODUCTION

Among the plethora of *Daphniphyllum* alkaloids,¹ some possess a distinctive bridged 7-azabicyclo[4.3.1]decane ring system embedded in their skeleton. Representative alkaloids with this structural feature, which is a homoanalogue of the morphan nucleus, include daphnicyclidins,² daphnillonins,³ and macropodumines⁴ (Figure 1). Additionally, a fused pyrrolidine ring completes the characteristic ABC framework of octahydro-1,7-ethanocyclohepta[*b*]pyrrole (colored blue in Figure 1).

Due to their structural complexity, the first total synthesis of one of these alkaloids, daphnillolin B, was not achieved until 2023 by Li.⁵ Also noteworthy are the total syntheses of several *Daphniphyllum* alkaloids recently reported by Li.⁹ Moreover, only a few studies have reported synthetic strategies toward

compounds embodying tricyclic scaffolds (ABC rings)⁶ as potential advanced precursors of the target alkaloids.

Previous synthetic approaches to the ABC tricyclic substructure of perhydro-7,1-ethanocyclohepta[*b*]pyrrole have been described in studies of the synthesis of daphnicyclidin A (Scheme 1). (a) Williams^{6a} transformed an intermediate bearing a nine-membered ring into an azabicyclic dione, which after an intramolecular reductive amination furnished the targeted compound. (b) The synthesis of Yang^{6b} involved a 2,3,4-*cis* trisubstituted pyrrolidine as an advanced intermediate, which allowed the construction of rings A and B by means of two intramolecular Horner–Wadsworth–Emmons reactions. (c) Harmata^{6c,d} described an intramolecular [4+3] cycloaddition of the salt generated from N-alkylation of a 5-hydroxynicotinic acid with a dienyl tosylate.

Gaining access to functionalized building blocks bearing this ABC skeleton would constitute a starting point for exploring new strategies toward the aforementioned alkaloids. Our interest was focused on accessing valuable advanced structures to facilitate studies aimed at the synthesis of 2-deoxymacropodumine A (Figure 1). With this objective, we planned to synthesize a functionalized azatricyclic building block with





Figure 1. *Daphniphyllum* alkaloids containing the azatricyclic 7/6/5 fragment (ABC core).

Received: May 3, 2024
Revised: June 21, 2024
Accepted: June 26, 2024
Published: July 1, 2024




Scheme 1. Precedents for the Synthesis of the ABC [7,6,5] Ring System



scaffold I through two approaches, starting from either functionalized azatricyclo II or azabicyclo III, each of which would undergo expansion of the cyclohexanone A ring to the corresponding seven-membered ring^{7,8} (Scheme 2). To

Scheme 2. Retrosynthetic Strategy for the Assembly of Azatricyclo I and Synthesis of Homomorphans V




evaluate the synthetic protocol for the ring enlargement, easily available morphans (IV) bearing a basic nitrogen atom or lactam unit would be used in preliminary studies to obtain homomorphans derivatives (V). Subsequently, the tested methodology would be applied to develop a new route to key building block I.

In the field of *Daphniphyllum* alkaloid synthesis, despite significant development in recent decades,⁹ few synthetic studies have focused on alkaloids embodying aforementioned structure I (Scheme 2), whereas the use of compounds featuring azatricyclic II or azabicyclic III units as building blocks is unprecedented.⁸ Furthermore, few synthetic pathways have been reported so far for homomorphans-type bicyclic compounds (Scheme 3). The first synthesis, developed in Amat's group,¹⁰ was based on a ring-closing metathesis from a functionalized piperidine compound, which gave access to a potentially valuable keto lactam (Scheme 3a). In Chiba's radical procedure,¹¹ a vinyl azide was used as a radical precursor and a Mn(III) as a promoter in a straightforward route to the azabicyclic ring (Scheme 3b). The generation of the homomorphans ring via (4+3) cycloaddition of oxidopyridinium ions was introduced by Harmata (Scheme 3c).¹² Recently, Griffith¹³ reported a new approach to the synthesis of the 7-azabicyclo[4.3.1]decane ring system using an intramolecular Heck reaction (Scheme 3d).


RESULTS AND DISCUSSION

Preliminary Studies. Ring Enlargement of Morphans: Synthesis of 7-Azabicyclo[4.3.1]decan-3-ones. Initially, we decided to study the unprecedented carbocyclic ring expansion of morphan compounds from ketones 5 and 8 (series a–c) employing diazo derivative reagents,¹⁴ evaluating the regioselectivity of the Tiffeneau–Demjanov procedure, as well as the influence of the nitrogen atom functionality (amine, lactam, or carbamate) on the overall process (Scheme 4). The required morphans were prepared following the methodology developed by our group as outlined in Scheme 4.¹⁵


Scheme 3. Synthetic Precedents for Homomorphans

Scheme 4. Ring Expansion of Morphans: Synthesis of Homomorphans (1a–c and 2a–c)^a


a) Lactam series



b) Amine series



c) Carbamate series




^a(i) Compound **3** was synthesized in five steps (66% overall yield) from 1,4-cyclohexanedione monoethylene acetal;¹⁶ (ii) Bu₃SnH, AIBN, benzene, reflux; (iii) NaOH, EtOH, reflux; (iv) Dess-Martin periodinane, CH₂Cl₂, rt; (v) TMSCHN₂, BF₃·OEt₂, CH₂Cl₂, rt; (vi) (CH₂OH)₂, TsOH, benzene, reflux; (vii) LDA, MeI, –78 °C to rt; (viii) 10% HCl, THF, rt; (ix) LiAlH₄, AlCl₃, THF, rt; (x) DMP, NaHCO₃, CH₂Cl₂, rt; (xi) TMSCHN₂, BuLi, Et₂O/THF, –78 °C; then MeOH and SiO₂, –78 °C to rt; (xii) 10% HCl, rt; (xiii) ClCO₂Me, NaHCO₃, CHCl₃, reflux.

The results reported here constitute a new approach to the synthesis of B-homomorphans. Two different methodologies were tested using trimethylsilyl diazomethane in the presence of either a Lewis acid¹⁷ or a base.¹⁸ The latter procedure, in which the ring expansion step was triggered by nucleophilic addition of deprotonated TMSCHN₂ to the ketone in compounds **5** and **8**, followed by two protonation steps with

MeOH and SiO₂,¹⁹ gave better yields for the homomorphans (compounds **1** and **2**, series a–c). This process also provided the desired ring-enlargement product with better regioselectivity, with the carbonyl group remaining at the contiguous bridgehead carbon atom, as in the target alkaloids. Notably, the results in the amino series (**1b** and **2b**) were better than the poor yields observed in the lactam series (e.g., **1a** vs **1b**).

At this point, we decided to test the ring expansion method with a more demanding substrate, namely azatricyclo **9**, which has a 6,6,5 ring system (Scheme 5) and was previously

Scheme 5. Synthesis of the 7,6,5-Azatricyclic Scaffold by Ring Expansion of the Carbocyclic Ring in **9**



Entry	Reagents and conditions ^a	Treatment	Product (Yield) ^b
1	TMSCHN ₂ , BuLi Et ₂ O/THF, -78 °C	1. MeOH 2. SiO ₂	10a (28%) 10b (17%)
2	TMSCHN ₂ , BuLi Et ₂ O/THF, -78 °C	1. MeOH 2. 1 M HCl	10a (33%) 10b (15%)

^a0.14–0.18 mmol scale. ^bIsolated yield


synthesized by our group in a formal synthesis of *rac*-himalensine A.²⁰ The enlargement of the cyclohexanone subunit using the same reaction conditions as in the morphan series was not regioselective, and a 2:1 mixture of ketones **10a** and **10b** was isolated in 46% overall yield. This result was not sufficiently satisfactory to justify continuing with this approach toward the target compound, especially considering the laborious preparation of azatricyclo **9** [type II scaffold (Scheme 1)].

After these studies, we turned our attention to developing a method based on the ring expansion of an octahydroindole [type III (Scheme 2)] for an efficient synthesis of a functionalized octahydro-*cis*-cyclohepta[*b*]pyrrole.²¹ The latter would then serve as an advanced intermediate en route to the functionalized 7,6,5-targeted azatricyclic scaffold.

On the basis of the results of the B-homomorphous synthesis, initially an amino derivative was prepared (Scheme 6a). Starting from octahydroindole **11**, previously described in our group,²² we reduced the lactam moiety, and further ketal hydrolysis provided amino ketone **12** in 64% over two steps. However, upon the reaction of ketone **13a** with TMSCHN₂ and BuLi and further treatment with MeOH and SiO₂, only complex mixtures of unidentifiable products were observed.

However, when the ketone homologation reaction was tested directly on octahydroindole **13**²³ (Scheme 6b), by treatment with a solution of TMSCHN₂ and BuLi, only regioisomer **14** was obtained in good yield. Epoxide **15** and silylenol ether **16** derivatives were also isolated but in low yields. Scheme 7 depicts the proposed mechanism^{14b} for the


Scheme 7




formation of the desired ketone **14** and byproducts **15** and **16**. Thus, treatment of TMSCHN₂ with BuLi and further addition of the more nucleophilic species **A** to the ketone substrate rendered intermediate **B**. As the ring expansion occurred after the key protonation step, giving **C** or **D**, multiple carbon insertions were avoided. Moreover, the choice of protonation source could determine the proportion of the obtained compounds (I–III).

Considering the good yield obtained for **14**, a new synthetic route was explored for the construction of the azatricyclic [5–6–7] ring core (Scheme 8). Thus, after ketone protection, hydroboration and oxidation of the allylic moiety in **17** gave

Scheme 6. Ring Expansion Process from Octahydroindoles **12 and **13****



Scheme 8. Synthesis of 5/6/7 Azatricyclic Building Block 25 from Azabicyclo 14



alcohol **18** in 94% yield. Subsequent hydroxyl protection as a methoxy group by treatment with NaH and iodomethane afforded compound **19** in 87% yield.²⁴ The reduction of lactam **19** provided tertiary amine **20**, which after N-debenzylation under hydrogenation conditions gave secondary amine **21**. The latter, upon treatment with trichloroacetyl chloride, afforded trichloroacetamide **22**. After hydrolysis of the acetal group, ketone **23** was isolated in 54% overall yield for the four-step sequence.

Taking advantage of the location of the C-5 carbonyl, we decided to prepare an enone that would allow radical closure of the B ring. Thus, trichloroacetamide **23** was oxidized with IBX in the presence of *p*-TsOH²⁵ to furnish enone **24**, which was isolated in 60% yield, along with traces of an overoxidized compound **24b** (see the [Experimental Section](#)). Finally, we addressed the B ring closure, subjecting trichloroacetamide **24** to reductive radical conditions by the slow addition of AIBN and TBTH over 4 h.²⁶ This resulted in the formation of keto-lactam **25** bearing the azatricyclic [5–6–7] fragment in 72% yield.

Notably, the regioselectivity attained in the ring expansion of azabicyclic ketone **13**, resulting in the formation of ketone **14**, afforded valuable azatricyclic ketone **25**. The relative position of the carbonyl group in **25** is consistent with that of alkaloids bearing a 5–6–7 azatricyclic subunit. Interestingly, this regioselectivity differs from that reported by Xie and She,⁸ who applied the ring expansion to a related compound also under the Tiffeneau–Demjanov reaction conditions.

CONCLUSIONS

In summary, the [5,6,7] azatricyclic core of 2-deoxymacropodumine A was achieved via a ring expansion process for the installation of the seven-membered ring. The ketone homologation methodology was first applied to morphan compounds, providing a new pathway for the synthesis of homomorphans. More notably, its subsequent application to

octahydroindolones (AC ring of the target alkaloids) allowed us to establish a novel synthetic route to ABC azatricyclic building blocks for use in alkaloid synthesis. The reported results pave the way for a synthetic proposal aimed at achieving the total synthesis for 2-deoxymacropodumine A.

EXPERIMENTAL SECTION

General. All reactions were carried out under an argon atmosphere with dry, freshly distilled solvents under anhydrous conditions. An oil bath was used as the heat source for the reactions that require heating. All product mixtures were analyzed by thin-layer chromatography using TLC silica gel plates with a fluorescent indicator ($\lambda = 254$ nm). Analytical thin-layer chromatography was performed on SiO₂ (Merck silica gel 60 F₂₅₄), and the spots were located by ultraviolet light and/or an aqueous 1% KMnO₄ solution or hexachloroplatinate reagent. Chromatography refers to flash chromatography and was carried out on SiO₂ (VWR 60, 40–63 μ m) or Al₂O₃ (neutral aluminum oxide, 0.063–0.2 mm). Organic extracts were dried during the reaction workup over anhydrous Na₂SO₄. Organic solvents were removed under vacuum using a rotatory evaporator. The reaction conditions for the ring expansion (for the safe use and quenching of TMSCHN₂) are those reported by Gaich in ref **19**. The small scale of the reactions minimized the potential risk of the reagents used. Chemical shifts of ¹H and ¹³C nuclear magnetic resonance (NMR) spectra are reported in parts per million downfield (δ) from Me₄Si (δ 0.00) and CDCl₃ (δ 77.00), respectively. All NMR data assignments are supported by gCOSY and gHSQC experiments. HRMS were obtained with an LC/MSD-TOF spectrometer (Agilent technologies, ESI-MS).

Synthesis of Morphans 5 and 8. Compound **5a** was prepared following our previously reported procedure.²⁷

(1*R*,5*R*)-2-Benzyl-2-azabicyclo[3.3.1]nonan-6-one (**5b**). To a solution of AlCl₃ (1.36 g, 9.9 mmol, 1.5 equiv) in tetrahydrofuran (THF, 30 mL) was added a 1 M solution of LiAlH₄ in THF (16.6 mL, 16.6 mmol, 2.5 equiv) at 0 °C, and the mixture was stirred for 20 min at room temperature (rt). Then, a solution of morphan **4** (1.9 g, 6.6 mmol) in THF (70 mL) was added dropwise via cannula, and the reaction mixture was stirred overnight at rt. The reaction was quenched with a 30% KOH solution, and the mixture extracted sequentially with CH₂Cl₂ (3 \times 30 mL), CHCl₃ (3 \times 25 mL), and a

$\text{CHCl}_3/i\text{-PrOH}$ mixture (4:1, 2×25 mL). The organics were dried and concentrated to yield the corresponding aminoalcohol that was pure enough to be used in the next step without further purification. The residue (1.35 g, 5.8 mmol) was diluted in CH_2Cl_2 (100 mL), and NaHCO_3 (3.66 g, 43.8 mmol, 7.5 equiv) was added followed by Dess-Martin periodinane (4.94 g, 11.6 mmol, 2.5 equiv). The reaction mixture was stirred at room temperature for 3 h, before the reaction was quenched with a saturated $\text{Na}_2\text{S}_2\text{O}_3/\text{Na}_2\text{CO}_3$ solution (1:1, 130 mL). After being stirred for 30 min, the mixture was poured into water (100 mL) and extracted with CH_2Cl_2 (3×100 mL). The combined organics were dried, filtered, and concentrated to obtain a yellow crude residue. After chromatography (Al_2O_3 , 9:1 hexane/ EtOAc), compound **5b** was isolated (0.82 g, 54% over two steps) as a transparent oil: IR (NaCl) 2932, 2808, 1705, 1447, 1123 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.36–7.23 (m, 5H, Ph), 3.68 and 3.60 (2d, $J = 13.2$ Hz, 1H each, CH_2Ph), 3.09 (br s, 1H, H-1), 2.69 (ddd, $J = 12.4, 6.0, 2.2$ Hz, 1H, H-3), 2.57–2.50 (m, 2H, H-5 and H-7), 2.48 (ddd, $J = 12.4, 12.4, 4$ Hz, 1H, H-3), 2.38 (dd, $J = 18.0, 7.4$ Hz, 1H, H-7), 2.30–2.22 (m, 1H, H-8), 2.08 (ddt, $J = 13.6, 2.8, 2.8$ Hz, 1H, H-9), 2.00–1.91 (m, 2H, H-9 and H-4), 1.81–1.69 (m, 2H, H-4 and H-8); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 216.5 (C-6), 138.9, 128.7, 128.2, and 126.9 (Ph), 59.6 (CH_2Ph), 49.7 (C-1), 46.0 (C-3), 42.8 (C-5), 38.8 (C-7), 31.7 (C-9), 29.2 (C-4), 21.1 (C-8); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{NO}$ 230.1539, found 230.1543.

(1*RS*,5*RS*)-2-Methoxycarbonyl-2-azabicyclo[3.3.1]nonan-6-one (**5c**).²⁸ To a solution of compound **5b** (0.12 g, 0.52 mmol, 1 equiv) in dry CHCl_3 (2 mL) were added NaHCO_3 (0.66 g, 7.9 mmol, 15 equiv) and methyl chloroformate (0.84 g, 0.69 mL, 8.9 mmol, 17 equiv). The reaction mixture was placed in a sealed tube and stirred at reflux overnight. Then, the mixture was cooled to room temperature and diluted with CH_2Cl_2 (10 mL), and the organic layer was washed with water, dried, and concentrated. The crude residue was purified by chromatography (1:0 \rightarrow 3:1 hexane/ EtOAc), providing **5c** as a colorless oil (89 mg, 86%): IR (neat) 2942, 1695, 1450, 1215 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 4.59 and 4.44 (2 bs, 1H, H-1), 4.02–3.91 (m, 1H, H-3), 3.74 (s, 3H, OMe), 3.22 (dd, $J = 13.6$ Hz, 1H, H-3), 2.66 (m, 2H, H-5), 2.54–2.48 (m, 2H, H-7) 2.11 (br s, 2H, H-8), 2.01 (br s, 2H, H-9), 1.90–1.88 (m, 2H, H-4); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 214 and 213.6 (C-6), 156.3 (CO_2Me), 52.6 (OMe), 44.8 and 44.6 (C-1), 42.2 (C-5), 38.9 (C-3), 37.7 (C-7), 31.0 and 30.8 (C-9), 29.4 and 28.7 (C-8), 27.9 and 27.6 (C-4). The NMR spectroscopy data matched the previously reported data.

(1*RS*,5*SR*)-2-Benzyl-2-azabicyclo[3.3.1]nonan-3,6-dione Ethylene Acetal (**6**). A solution of morphan **5a** (0.71 g, 2.9 mmol, 1 equiv), *p*-TsOH (0.22 g, 1.16 mmol, 0.4 equiv), and ethylene glycol (8.1 mL, 145 mmol, 50 equiv) in toluene (70 mL) was placed in a Dean-Stark setup and heated to reflux for 4 h. After the mixture had been cooled, the reaction was quenched with a saturated NaHCO_3 solution (50 mL). The aqueous layer was extracted with EtOAc (4×20 mL), and the combined organics were washed with brine (1×40 mL), dried, filtered, and concentrated to obtain a yellow crude product. After purification (1:0 \rightarrow 3:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$), product **6** was obtained (0.71 g, 85%) as a colorless oil: IR (NaCl) 2949, 1635, 1452, 1107 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.33–7.25 (m, 5H, Ph), 5.27 (d, $J = 15.2$ Hz, 1H, CH_2Ph), 4.01–3.88 (m, 5H, OCH_2 and CH_2Ph), 3.44 (br s, 1H, H-1), 2.75 (d, $J = 18.8$ Hz, 1H, H-4), 2.62 (dd, $J = 18.8, 7.2$ Hz, 1H, H-4), 2.09–2.08 (m, 1H, H-5), 2.03 (br d, $J = 13.0$ Hz, 1H, H-9), 1.83–1.78 (m, 2H, H-9 and H-7), 1.67–1.57 (m, 3H, H-7 and H-8); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 170.1 (C-3), 137.6, 128.6, 127.8, and 127.3 (Ph), 109.6 (C-6), 64.6 and 64.5 (OCH_2), 50.2 (C-1), 48.1 (CH_2Ph), 36.2 (C-5), 34.0 (C-4), 29.9 (C-9), 27.2 (C-7), 27.0 (C-8); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{22}\text{NO}_3$ 288.1594, found 288.1604.

(1*RS*,4*RS*,5*SR*)-2-Benzyl-2-azabicyclo[3.3.1]nonan-3,6-dione Ethylene Acetal (**7**). To a solution of lactam **6** (0.62 g, 2.19 mmol, 1 equiv) in THF (24 mL) cooled at -78°C was added dropwise a solution of LDA (1 M in THF, 4.4 mL, 2 equiv). After the mixture was stirred for 1 h, iodomethane (0.4 mL, 5.9 mmol, 2.7 equiv) was added, and the stirring was prolonged for 3 h. A saturated NH_4Cl solution (20 mL) was added, and the mixture was extracted

with EtOAc (4×20 mL). The organics were dried, filtered, and concentrated. The crude residue was purified by chromatography (1:0 \rightarrow 4:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$), and compound **7** was obtained (0.50 g, 77%) as a colorless oil: IR (NaCl) 2937, 1634, 1449, 1113 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.34–7.22 (m, 5H, Ph), 5.28 (d, $J = 14.8$ Hz, 1H, CH_2Ph), 3.99–3.87 (m, 5H, OCH_2 and CH_2Ph), 3.40 (br s, 1H, H-1), 2.78 (q, $J = 7.4$ Hz, 1H, H-4), 1.91 (br s, 2H, H-9), 1.81–1.69 (m, 3H, H-5 and H-8), 1.65–1.56 (m, 2H, H-7), 1.39 (d, $J = 7.4$ Hz, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 173.9 (C-3), 137.8, 128.6, 127.7, and 127.3 (Ph), 109.5 (C-6), 64.5 and 64.5 (OCH_2), 50.5 (C-1), 47.9 (CH_2Ph), 43.6 (C-5), 37.9 (C-4), 27.1 (C-7), 26.9 (C-8), 26.6 (C-9), 20.4 (Me); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{24}\text{NO}_3$ 302.1751, found 302.1753.

(1*RS*,4*RS*,5*SR*)-2-Benzyl-4-methyl-2-azabicyclo[3.3.1]nonan-3,6-dione (**8a**). To a solution of lactam **7** (113 mg, 0.38 mmol) in THF (4 mL) was added a 10% HCl solution (8 mL). After the mixture was stirred overnight at room temperature, Na_2CO_3 (20 mL) was added, and the mixture was extracted with CH_2Cl_2 (4×10 mL). The organics were dried, filtered, concentrated, and purified by chromatography (1:0 \rightarrow 9:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$). Compound **8a** was obtained as a colorless oil (92 mg, 95%): ^1H NMR (400 MHz, CDCl_3) δ 7.36–7.26 (Ph), 5.34 and 4.05 (2d, $J = 15.0$ Hz, 1H each, CH_2Ph), 3.63 (br s, 1H, H-1), 2.59 (q, $J = 7.6$ Hz, 1H, H-4), 2.56 (br s, 1H, H-5), 2.46 (dd, $J = 13.4, 7.2$ Hz, 1H, H-7), 2.39–2.33 (m, 1H, H-7), 2.26 (dq, $J = 13.6, 3.6$ Hz, 1H, H-9), 2.23–2.16 (m, 1H, H-8), 1.93 (dm, $J = 13.6$ Hz, 1H, H-9), 1.77 (tdd, $J = 13.6, 5.4, 2.6$ Hz, 1H, H-8), 1.45 (d, $J = 7.6$ Hz, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 210.8 (C-6), 172.2 (C-3), 137.3, 128.8, 127.8, and 127.3 (Ph), 51.2 (C-5), 50.3 (C-1), 48.3 (CH_2Ph), 39.2 (C-4), 34.2 (C-7), 29.5 (C-8), 28.5 (C-9), 19.9 (Me); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{20}\text{NO}_3$ 258.1489, found 258.1497.

(1*RS*,4*RS*,5*SR*)-2-Benzyl-4-methyl-2-azabicyclo[3.3.1]nonan-6-one (**8b**). To a solution of AlCl_3 (0.18 g, 1.35 mmol, 1.5 equiv) in THF (4 mL) was added dropwise a solution of LiAlH_4 (1 M in THF, 1.8 mL, 2 equiv) at room temperature. After the mixture was stirred for 30 min, a solution of lactam **7** (0.27 g, 0.9 mmol, 1 equiv) was added dropwise via cannula. The reaction mixture was stirred overnight and cooled to 0°C , and the reaction quenched with a 30% KOH aqueous solution. The mixture was extracted with CH_2Cl_2 (4×15 mL), and the combined organics were dried, filtered, and concentrated. The residue was diluted in a 10% HCl aqueous solution (5 mL), and the reaction mixture was stirred overnight at room temperature. Then, the reaction was quenched with 15% NaOH, and the mixture was extracted with CH_2Cl_2 (5×10 mL). The organics were dried, filtered, and concentrated. After chromatography (Al_2O_3 , 98:2 hexane/ EtOAc), aminoketone **8b** (0.18 g, 83% over two steps) was isolated as a colorless oil: IR (NaCl) 2926, 1704, 1425 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.34–7.21 (m, 5H, Ph), 3.63 and 3.57 (2d, $J = 13.6$ Hz, 1H each, CH_2Ph), 3.07 (br s, 1H, H-1), 2.58 (dd, $J = 12.2, 5.6$ Hz, 1H, H-3), 2.54 (dd, $J = 8.8, 5.6$ Hz, 1H, H-7), 2.49 (dd, $J = 8.8, 5.6$ Hz, 1H, H-7), 2.34–2.29 (m, 1H, H-9), 2.30 (dd, $J = 12.2, 3.8$ Hz, 1H, H-3), 2.24 (br d, $J = 2.4$ Hz, 1H, H-5), 2.17–2.10 (m, 1H, H-8), 2.08–2.05 (m, 1H, H-4), 1.78–1.68 (m, 1H, H-8), 1.16 (d, $J = 6.8$ Hz, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 216.5 (C-6), 139.5, 128.4, 128.2, and 126.9 (Ph), 59.6 (CH_2Ph), 51.4 (C-3), 51.0 (C-1), 48.8 (C-5), 37.4 (C-7), 33.2 (C-4), 25.9 (C-9), 22.2 (C-8), 18.6 (Me); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{NO}$ 244.1696, found 244.1703.

(1*RS*,4*RS*,5*SR*)-2-Methoxycarbonyl-2-azabicyclo[3.3.1]nonan-6-one (**8c**). To a solution of **8b** (105 mg, 0.43 mmol, 1 equiv) in dry CHCl_3 (1.5 mL) were added NaHCO_3 (0.54 g, 6.47 mmol, 15 equiv) and methyl chloroformate (0.69 g, 0.57 mL, 7.3 mmol, 17 equiv). The reaction mixture was placed in a sealed tube and stirred at reflux overnight. The mixture was cooled to room temperature and diluted with CH_2Cl_2 (10 mL), and the organic layer was washed with water, dried, and concentrated. The crude residue was purified by chromatography (1:0 \rightarrow 3:1 hexane/ EtOAc), providing **8c** as a colorless oil (69 mg, 75%): IR (neat) 2956, 2873, 1699, 1447, 1230 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 4.43–4.28 (2 s, 1H, H-1), 3.71 (s, 3H, OMe), 3.58–3.48 (m, 1H, H-3), 3.31 (dm, $J = 13.6$ Hz, 1H,

H-3), 2.61 and 2.40 (2m, 1H each, H-7), 2.31 (s, 1H, H-5), 2.24 (m, 1H, H-9), 2.17 (m, 1H, H-8), 2.03 (s, 1H, H-4), 1.95 (m, 1H, H-8), 1.78 (m, 1H, H-9), 1.09 (s, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 213.8 and 213.3 (C-6), 156.8 and 156.6 (CO_2Me), 52.7 and 52.5 (OMe), 48.8 (C-5), 45.4 and 45.3 (C-1), 44.3 and 44.2 (C-3), 35.7 and 35.4 (C-7), 31.6 and 31.4 (C-4), 29.1 and 28.1 (C-8), 26.3 and 25.7 (C-9), 19.0 and 18.7 (Me); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{18}\text{NO}_3$ 212.1281, found 212.1287.

Synthesis of Homomorphans 1. (1*RS*,6*SR*)-7-Benzyl-7-azabicyclo[4.3.1]decan-2,8-dione (**1a**). To a solution of $\text{BF}_3\cdot\text{OEt}_2$ (0.08 mL, 0.6 mmol, 1.3 equiv) in dry CH_2Cl_2 (5 mL) at 0 °C was added a solution of **5a** (0.105 g, 0.46 mmol) in CH_2Cl_2 (1.5 mL), followed by the addition of a TMSCHN_2 solution (2 M in hexane, 0.3 mL, 1.3 equiv). The reaction mixture was warmed to rt and stirred overnight. The mixture was diluted in Et_2O (5 mL), and the reaction quenched with an ice-cooled 2.5% NaHCO_3 solution. The organic layer was washed with brine, dried, and concentrated to give a yellow crude residue, which was purified by chromatography (1:0 \rightarrow 9:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$). Homomorphane **1a** (45 mg, 38%) was isolated as a colorless oil: IR (NaCl) 2930, 1698, 1638, 1450 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.33–7.23 (m, 5H, Ph), 5.32 and 3.97 (2 d, J = 15.0 Hz, 1H each, CH_2Ph), 3.77–3.73 (m, 1H, H-6), 3.06 (d, J = 18.0 Hz, 1H, H-9), 2.76–2.72 (m, 1H, H-1), 2.70–2.63 (m, 2H, H-9 and H-3), 2.59–2.54 (m, 1H, H-3), 2.29–2.25 (m, 2H, H-5 and H-10), 2.21–2.13 (m, 1H, H-10), 1.87–1.74 (m, 1H, H-4), 1.55–1.38 (m, 2H, H-4 and H-5); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 213.3 (C-2), 169.2 (C-8), 137.2, 128.6, 128.0, and 127.4 (Ph), 53.1 (C-6), 47.0 (CH_2Ph), 43.1 (C-3), 42.6 (C-1), 35.1 (C-9), 32.7 (C-5), 28.7 (C-10), 18.6 (C-4); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{20}\text{NO}_2$ 258.1489, found 258.1494.

(1*RS*,6*RS*)-7-Benzyl-7-azabicyclo[4.3.1]decan-2-one (**1b**). BuLi (2.5 M in hexanes, 1.92 mL, 4.8 mmol, 2.25 equiv) was added to Et_2O at –78 °C followed by the addition of TMSCHN_2 (0.6 M in hexanes, 8 mL, 4.8 mmol, 2.25 equiv). After the mixture was stirred for 40 min, a solution of **5b** (0.49 g, 2.1 mmol) in THF (53 mL) was added slowly over 20 min with a syringe pump. The reaction mixture was stirred at –78 °C for 2 h; then, a solution of MeOH/THF (1:9, 20 mL) was added, and the mixture was stirred at room temperature for 30 min. A solution of 2 M NaOH was added; the phases were separated, and the aqueous layer was extracted sequentially with CH_2Cl_2 (2 \times 50 mL), CHCl_3 (3 \times 50 mL), and a $\text{CHCl}_3/i\text{-PrOH}$ mixture (4:1, 2 \times 25 mL). To the combined organics were added SiO_2 and Na_2SO_4 , and the mixture was stirred at room temperature for 40 min. The reaction mixture was filtered through a Celite pad and concentrated to yield a crude residue, which was purified by chromatography (Al_2O_3 , 1:0 \rightarrow 9.8:0.2 hexane/ EtOAc), providing **1b** as a white solid (0.35 g, 67%): mp 78–81 °C; IR (NaCl) 2952, 2360, 2342, 1696, 1446 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 3.83 and 3.25 (2d, J = 14.4 Hz, 1H each, CH_2Ph), 2.94 (bt, 1H, H-6), 2.82 (td, J = 12, 4 Hz, 1H, H-3), 2.56–2.47 (m, 2H, H-3, H-8), 2.45 (ddt, J = 14.4, 7.6, 2 Hz, 1H, H-9), 2.32 (dtd, J = 7.6, 3.6, 1.6 Hz, H-1), 2.29–2.20 (m, 2H, H-5, H-8), 2.13 (ddd, J = 14.4, 3.6, 1.8 Hz, 1H, H-10), 2.06 (ddd, J = 14.4, 7.6, 3.6 Hz, 1H, H-10), 1.86–1.74 (m, 2H, H-4), 1.71–1.63 (m, 1H, H-9), 1.48 (dddd, J = 14.8, 12.4, 5.4, 2.8 Hz, 1H, H-5); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 215.5 (C-2), 139.5, 128.3, 128.0, and 126.7 (Ph), 57.7 (CH_2Ph), 55.9 (C-6), 44.9 (C-8), 43.2 (C-3), 41.9 (C-1), 32.4 (C-5), 30.2 (C-10), 27.6 (C-9), 21.9 (C-4); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{NO}$ 244.1696, found 244.1701.

(1*RS*,6*RS*)-7-Methoxycarbonyl-7-azabicyclo[4.3.1]decan-2-one (**1c**). Morphan **5c** (88 mg, 0.45 mmol, 1 equiv) was subjected to the ring expansion procedure being performed as described before for **1a** synthesis. After chromatography (1:0 \rightarrow 9:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$), homomorphane **1c** was obtained as an oil (28.9 mg, 31%) along with **1c'** (36.2 mg, 38%): IR (neat) 2952, 1697, 1447 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 4.55 and 4.44 (2 s, 1H, H-6), 4.10 and 3.95 (2d, J = 11.6 Hz, 1H, H-8), 3.70 (s, 3H, OMe), 2.95–2.78 (m, 2H, H-8 and H-3), 2.62–2.58 (m, 1H, H-1), 2.54 (dd, J = 13.0, 6.6 Hz, 1H, H-3), 2.21–2.17 (m, 3H, H-10, H-9 and H-5), 2.03–1.89 (m, 2H, H-10 and H-4), 1.72–1.58 (m, 3H, H-9, H-5 and H-4); $^{13}\text{C}\{^1\text{H}\}$ NMR

(101 MHz, CDCl_3) δ 216.4 and 216.3 (C-2), 156.5 and 156.2 (CO_2Me), 52.5 (OMe), 48.5 (C-6), 44.1 (C-3), 43.0 (C-1), 40.4 (C-8), 35.9 and 34.9 (C-5), 29.5 (C-10), 28.3 (C-9), 21.7 (C-4); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{18}\text{NO}_3$ 212.1281, found 212.1289.

(1*RS*,6*RS*)-7-Methoxycarbonyl-7-azabicyclo[4.3.1]decan-3-one (**1c'**). IR (neat) 2932, 1697, 1448 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 4.59 and 4.46 (2d, J = 6.2 Hz, 1H, H-6), 3.86 (2 dt, J = 14.0, 4.8 Hz, 1H, H-8), 3.70 (s, 3H, OMe), 3.21 (t, J = 12.8 Hz, 1H, H-8), 2.65 (2 dd, J = 16.8, 5.2 Hz, 1H each, H-2), 2.58–2.42 (m, 2H, H-4), 2.28 (m, 1H, H-1), 2.02–1.96 (m, 3H, H-5 and H-10), 1.82–1.72 (m, 2H, H-9 and H-10), 1.65–1.59 (m, 1H, H-9); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 213.3 and 212.8 (C-3), 156.3 and 156.3 (CO_2Me), 52.6 and 52.5 (OMe), 48.1 and 47.4 (C-6), 47.8 and 47.4 (C-2), 40.3 and 40.2 (C-4), 36.6 and 36.5 (C-8), 32.2 (C-10), 29.5 and 29.9 (C-9), 27.9 and 27.4 (C-5), 24.2 and 24.1 (C-1); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{18}\text{NO}_3$ 212.1281, found 212.1287.

Synthesis of Homomorphans 2. (1*RS*,6*SR*,9*SR*)-7-Benzyl-9-methyl-7-azabicyclo[4.3.1]decan-2-one (**2b**). Morphan **8b** (0.22 g, 0.91 mmol, 1 equiv) was subjected to ring expansion following the procedure for **1b** reported above. After chromatography (Al_2O_3 , 1:0 \rightarrow 9.8:0.2 hexane/ EtOAc), homomorphane **2b** was obtained as waxy solid (0.154 g, 66% yield) along with **2b'** (31 mg, 13%): ^1H NMR (400 MHz, CDCl_3) δ 7.32–7.19 (m, 5H, Ph), 3.87 and 3.04 (2d, J = 14.4 Hz, 1H each, CH_2Ph), 2.93–2.88 (m, 1H, H-9), 2.83–2.76 (m, 2H, H-6 and H-3), 2.57 (dd, J = 11.6, 8.4 Hz, 1H, H-8), 2.50 (ddd, J = 11.6, 6.4, 1.6 Hz, 1H, H-3), 2.23 (ddd, J = 14.4, 7.8, 4.0 Hz, 1H, H-5), 2.07 (dddd, J = 15.0, 8.4, 3.6, 0.8 Hz, 1H, H-10), 1.98 (dd, J = 15.0, 3.4 Hz, 1H, H-10), 1.91–1.79 (m, 2H, H-1 and H-4), 1.75–1.68 (m, 1H, H-4), 1.64 (dd, J = 11.6, 9.6 Hz, 1H, H-8), 1.50 (ddd, J = 14.4, 13.2, 4.8, 1.2 Hz, 1H, H-5), 0.88 (d, J = 6.8 Hz, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 214.7 (C-2), 139.6, 128.3, 127.9, 126.6 (Ph), 57.1 (CH_2Ph), 57.0 (C-6), 53.2 (C-8), 49.0 (C-1), 43.1 (C-3), 33.3 (C-5), 32.1 (C-9), 26.5 (C-10), 21.5 (C-4), 18.0 (Me); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{24}\text{NO}$ 258.1852, found 258.1860.

(1*RS*,6*RS*,9*RS*)-7-Benzyl-9-methyl-7-azabicyclo[4.3.1]decan-3-one (**2b'**). ^1H NMR (400 MHz, CDCl_3) δ 7.32–7.21 (m, 5H, Ph), 3.68 and 3.40 (2d, J = 13.8 Hz, 1H each, CH_2Ph), 3.05 (br q, J = 5.6 Hz, 1H, H-6), 2.68 (ddd, J = 15.6, 8.8, 6.8 Hz, 1H, H-4), 2.64–2.57 (m, 1H, H-8), 2.61 (d, J = 6.0 Hz, 2H, H-2), 2.38 (ddd, J = 15.6, 6.8, 6.0 Hz, 1H, H-4), 2.27–2.21 (m, 1H, H-10), 2.14–2.03 (m, 2H, H-8 and H-5), 1.82–1.77 (m, 1H, H-9), 1.76–1.71 (m, 1H, H-1), 1.69–1.60 (m, 1H, H-5), 1.47 (br d, J = 14.4 Hz, 1H, H-10), 0.95 (d, J = 6.8 Hz, 1H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 213.1 (C-3), 139.4, 128.4, 128.2, and 126.8 (Ph), 59.5 (CH_2Ph), 54.4 (C-6), 50.6 (C-8), 50.4 (C-2), 40.0 (C-4), 33.6 (C-9), 32.3 (C-1), 29.9 (C-10), 25.3 (C-5), 19.4 (Me); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{24}\text{NO}$ 258.1852, found 258.1855.

(1*RS*,6*SR*,9*SR*)-7-Methoxycarbonyl-9-methyl-7-azabicyclo[4.3.1]decan-2-one (**2c**). Morphan **8c** (50 mg, 0.24 mmol, 1 equiv) was subjected to the ring expansion procedure being performed as described above for the preparation of **1b**. After chromatography (1:0 \rightarrow 9:1 $\text{CH}_2\text{Cl}_2/\text{EtOAc}$), homomorphane **2c** was obtained as a colorless oil (30 mg, 56%) along with **2c'** (7.5 mg, 14%): IR (neat) 2954, 2874, 1697, 1448 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 4.48 and 4.43 (2 s, 1H, H-6), 3.70 (s, 3H, OMe), 3.59 (br s, 1H, H-8), 3.18 (dd, J = 14.0, 3.6 Hz, 1H, H-8), 2.80 (dd, J = 13.6, 4.8 Hz, 1H, H-3), 2.56 (dd, J = 13.6, 6.6 Hz, 1H, H-3), 2.39 (br s, 1H, H-9), 2.30 (br s, 1H, H-1), 2.24–2.19 (m, 2H, H-10 and H-5), 1.99 (d, J = 14.8 Hz, 1H, H-10), 1.90–1.85 (m, 1H, H-4), 1.78–1.61 (m, 2H, H-5 and H-4), 1.09 (d, J = 7.2 Hz, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 216.1 (C-2), 156.9 (CO), 52.5 (OMe), 49.5 (C-1), 48.6 (C-6), 45.4 (C-8), 43.8 (C-3), 31.1 (C-9), 24.1 (C-10), 21.6 (C-4), 17.7 (Me) (the signal for C-5 was not observed); HRMS (ESI-TOF) m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{20}\text{NO}_3$ 226.1438, found 226.1445.

Ring Expansion from Azatricyclo 9. (3*RS*,3*aSR*,7*SR*,8*aSR*,9*RS*)-3-Allyl-3*a*,9-dimethylhexahydro-2*H*-7,1-ethanocyclohepta[b]pyrrole-2,6(3*H*)-dione (**10a**). Tricyclic compound **9** (34 mg, 0.14 mmol, 1 equiv) was subjected to the ring expansion procedure being

performed as described before for the preparation of **1b**. After purification by chromatography (1:0 → 3:2 hexane/EtOAc), homologated compound **10a** was obtained as a colorless oil (11.7 mg, 33%) along with compound **10b** (5.4 mg, 15%): IR (NaCl) 2955, 1694, 1456, 1434, 912 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 6.00–5.90 (m, 1H, =CH), 5.13 (d, J = 16.8 Hz, 1H, =CH₂, H-*trans*), 5.04 (d, J = 10.0 Hz, 1H, =CH₂, H-*cis*), 4.08 (dd, J = 13.6, 7.6 Hz, 1H, H-10), 3.63–3.61 (m, 1H, H-8a), 2.69–2.62 (m, 1H, CH₂-3), 2.50–2.45 (m, 2H, H-5), 2.43–2.30 (m, 3H, H-10, H-3, and H-7), 2.16–2.03 (m, 4H, H-8, CH₂-3, and H-9), 1.71 (ddd, J = 15.5, 8.8, 2.4 Hz, 1H, H-4), 1.48 (ddd, J = 15.5, 9.6, 4.0 Hz, 1H, H-4), 1.17 (s, 3H, Me-3a), 1.08 (d, J = 6.8 Hz, 3H, Me-9); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 212.7 (C-6), 174.3 (C-2), 137.1 (=CH₂), 116.1 (=CH), 60.3 (C-8a), 52.5 (C-3), 50.6 (C-7), 45.2 (C-3a), 40.9 (C-10), 37.4 (C-5), 31.6 (C-9), 29.3 (CH₂-3), 27.2 (C-4), 24.2 (Me-3a), 20.4 (Me-9), 19.2 (C-8); HRMS (ESI-TOF) m/z [$M + H$]⁺ calcd for $\text{C}_{16}\text{H}_{24}\text{NO}_2$ 262.1802, found 262.1811.

(3*RS*,3*aSR*,7*RS*,8*aSR*,9*RS*)-3-Allyl-3*a*,9-dimethylhexahydro-2*H*-7,1-ethanocyclohepta[b]pyrrole-2,5(3*H*)-dione (**10b**). IR (NaCl) 2957, 1699, 1459, 903 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 5.98–5.88 (m, 1H, =CH), 5.17 (br d, J = 17 Hz, 1H, =CH₂, H-*trans*), 5.02 (br d, J = 10 Hz, 1H, =CH₂, H-*cis*), 4.00 (dd, J = 13.6, 8.0 Hz, 1H, H-10), 3.58 (d, J = 8.4 Hz, 1H, H-8a), 2.88–2.80 (m, 1H, CH₂-3), 2.64 (dd, J = 12.0, 7.2 Hz, 1H, H-6), 2.55–2.50 (m, 1H, CH₂-3), 2.48 and 2.40 (2d, J = 11.8 Hz, 1H each, H-4), 2.35–2.19 (m, 4H, H-6, H-10, H-3, and H-8), 2.02 (dd, J = 15.4, 2.2 Hz, H-8), 1.95–1.88 (m, 2H, H-7 and H-9), 1.18 (s, 3H, Me-3a), 0.96 (d, J = 6.8 Hz, Me-9); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 208.1 (C-5), 172.7 (C-2), 137.4 (=CH), 116.0 (=CH₂), 61.1 (C-8a), 54.5 (C-6), 52.0 (C-3), 45.9 (C-4), 44.1 (C-3a), 41.1 (C-10), 33.5 (C-9), 32.9 (C-7), 30.3 (CH₂-3), 25.7 (Me-3a), 22.0 (C-8), 20.0 (Me-9).

(3*RS*,3*aSR*,7*aSR*)-3-Allyl-1-benzyl-3*a*-methyloctahydro-5*H*-indol-5-one (**12**). To a cooled (0 °C) suspension of AlCl_3 (0.29 g, 2.18 mmol, 1.5 equiv) in THF (7 mL) was added a solution of LiAlH_4 (1 M in THF, 2.9 mL, 2 equiv). After being stirred at this temperature for 20 min, a solution of compound **11**²² (0.5 g, 1.45 mmol, 1 equiv) in THF (14 mL) was added via cannula, and the reaction mixture was stirred at room temperature overnight. Next, the reaction was quenched with a 30% KOH solution (20 mL), and the mixture extracted with a CHCl_3 /*i*-PrOH mixture (4:1, 4 × 20 mL). The combined organics were dried, filtered, and concentrated to afford a crude residue, which was diluted in 10% HCl (30 mL) and stirred overnight. After basification with a 15% NaOH solution (40 mL), the mixture was extracted with CH_2Cl_2 (4 × 30 mL) and the combined organics were dried, filtered, concentrated, and purified by chromatography (9.5:0.5 → 4:1 hexane/EtOAc) to provide compound **12** (0.26 g, 64%) as a waxy solid: IR (NaCl) 3027, 2954, 1712, 1452, 912, 739, 699 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 5.66 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H, =CH), 4.97 (dq, J = 17.0 Hz, 1H, =CH₂, H-*trans*), 4.91 (ddt, J = 10.2, 2.1, 1.1 Hz, 1H, =CH₂, H-*cis*), 4.08 and 3.34 (2d, J = 13.6 Hz, 1H each, CH₂Ph), 2.80 (dd, J = 19.8, 13.8 Hz, 1H, H-6), 2.80 (dd, J = 10.4, 8.2 Hz, 1H, H-2), 2.63 (dd, J = 10.4, 9.6 Hz, 1H, H-2), 2.62 (d, J = 13.0 Hz, 1H, H-4), 2.53 (t, J = 2.6 Hz, 1H, H-7a), 2.20–2.05 (m, 3H, CH₂-3, H-7, and H-6), 1.88 (d, J = 13.0 Hz, 1H, H-4), 1.92–1.75 (m, 3H, H-3, H-7, and CH₂-3), 1.02 (s, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 212.9 (C-5), 139.9 (Ph), 137.1 (=CH), 128.3, 128.1, and 126.8 (Ph), 115.6 (=CH₂), 68.3 (C-7a), 58.0 (CH₂Ph), 56.8 (C-2), 47.8 (C-3a), 47.1 (C-3), 45.3 (C-4), 35.8 (C-6), 32.8 (C-7), 24.2 (CH₂-3), 22.9 (Me); HRMS (ESI-TOF) m/z [$M + H$]⁺ calcd for $\text{C}_{19}\text{H}_{26}\text{NO}$ 284.2009, found 284.2013.

Ring Expansion from Azatricyclo 13. (3*RS*,3*aSR*,8*aSR*)-1-Benzyl-3*a*-methyl-3-(prop-2-en-1-yl)hexahydrocyclohepta[b]pyrrole-2,5(1*H*,3*H*)-dione (**14**). Lactam **13**²³ (4.91 g, 16.5 mmol) was subjected to the ring expansion procedure being performed as described above for the preparation of **1b**. After chromatography (9:1 → 4:1 hexane/EtOAc), ring-expanded product **14** (3.81 g, 74%) was obtained as a waxy solid along with subproduct **15** (0.40 g, 8%) and silyl enol ether **16** (0.51 g, 8%). The NMR data for **14** matched those previously reported by our research group.²³ Epoxide **15**: IR (NaCl)

3065, 2938, 1690, 1432, 1411, 914, 732 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.26–7.13 (m, 5H, Ph), 5.95–5.85 (m, 1H, =CH), 5.05–4.91 (m, 3H, =CH₂ and CH₂Ph), 3.93 (d, J = 15.0 Hz, 1H, CH₂Ph), 3.11 (t, J = 3.1 Hz, 1H, H-7a), 2.60–2.54 (m, 1H, CH₂-3), 2.47 (s, 2H, OCH₂), 2.10 (dd, J = 8.6, 5.2 Hz, 1H, H-3), 2.08–1.99 (m, 1H, CH₂-3), 1.94–1.80 (m, 3H, H-7 and H-4), 1.57 (td, J = 13.5, 5.2 Hz, 1H, H-6), 1.19 (s, 3H, Me), 0.93–0.87 (m, 2H, H-6 and H-4); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 177.0 (C-2), 137.3 (=CH), 136.8, 128.6, 127.9, and 127.4 (Ph), 116.0 (=CH₂), 59.7 (C-7a), 56.1 (C-5), 54.6 (C-3), 52.0 (OCH₂), 44.1 (CH₂Ph), 41.2 (C-3a), 34.8 (C-4), 28.9 (CH₂-3), 26.6 (C-6), 22.8 (Me), 19.9 (C-7); HRMS (ESI-TOF) m/z [$M + H$]⁺ calcd for $\text{C}_{20}\text{H}_{26}\text{NO}_2$ 312.1958, found 312.1967.

Silyl Enol Ether 16. IR (NaCl) 3066, 2957, 1690, 1433, 1251, 845, 733 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.33–7.18 (m, 5H, Ph), 5.99 (dddd, J = 17.0, 9.8, 8.0, 5.6 Hz, 1H, =CH), 5.15 (dd, J = 17.0 Hz, 1H, =CH₂, H-*trans*), 5.06 (d, J = 9.8 Hz, 1H, =CH₂, H-*cis*), 5.05 (d, J = 15.2 Hz, 1H, CH₂Ph), 4.88 (br t, J = 4.5 Hz, 1H, H-6), 3.94 (d, J = 15.2 Hz, 1H, CH₂Ph), 3.07 (dd, J = 9.2, 4.2 Hz, 1H, H-8a), 2.66 (d, J = 15.8 Hz, 1H, H-4), 2.65–2.58 (m, 1H, CH₂-3), 2.29 (dd, J = 8.2, 5.8, 1H, H-3), 2.20 (dt, J = 14.0, 8.0 Hz, 1H, CH₂-3), 2.06 (dt, J = 15.8, 7.0 Hz, 1H, H-7), 1.95–1.78 (m, 2H, H-7 and H-8), 1.78 (d, J = 15.8 Hz, 1H, H-4), 1.69–1.61 (m, 1H, H-8), 1.19 (s, 3H, Me), 0.16 (s, 9H, TMS); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 175.6 (C-2), 150.1 (C-5), 137.3 (=CH), 136.8, 128.6, 127.8, and 127.4 (Ph), 116.1 (=CH₂), 107.1 (C-6), 64.7 (C-8a), 53.5 (C-3), 43.8 (NCH₂), 42.1 (C-3a), 35.9 (C-4), 30.6 (CH₂-3), 27.5 (C-8), 25.1 (Me), 20.9 (C-7), 0.3 (TMS).

Synthesis of the ABC Ring System. (3*RS*,3*aSR*,8*aSR*)-1-Benzyl-3*a*-methyl-3-(prop-2-en-1-yl)hexahydrocyclohepta[b]pyrrole-2,5-(1*H*,3*H*)-dione Ethylene Acetal (**17**). To a solution of bicyclic lactam **14** (3.81 g, 12.2 mmol, 1 equiv) in toluene (250 mL) were added ethylene glycol (34.2 mL) and *p*-TsOH (0.93 g, 4.89 mmol, 0.4 equiv). The reaction mixture was heated to reflux with a Dean-Stark apparatus over 5 h. Then, after the mixture had cooled, a saturated NaHCO_3 solution (300 mL) was added and the mixture was extracted with EtOAc (3 × 150 mL). The combined organics were dried, filtered, concentrated, and purified by chromatography (9:1 → 4:1 hexane/EtOAc) to afford protected compound **17** (3.64 g, 84%) as a waxy solid: IR 2933, 1682, 1434, 1036, 700 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.34–7.20 (m, 5H, Ph), 6.00–5.90 (m, 1H, =CH), 5.13–5.01 (m, 3H, =CH₂ and CH₂Ph), 3.92–3.83 (m, 5H, OCH₂ and CH₂Ph), 2.98 (dd, J = 11.0, 2.0 Hz, 1H, H-8a), 2.49–2.40 (m, 2H, 3-CH₂), 2.15–2.10 (m, 1H, H-3), 2.12 (d, J = 13.8 Hz, 1H, H-4), 1.92–1.88 (m, 1H, H-8), 1.76–1.67 (m, 2H, H-7 and H-6), 1.62 (d, J = 13.8 Hz, 1H, H-4), 1.64–1.56 (m, 1H, H-6), 1.55–1.46 (m, 1H, H-8), 1.40–1.32 (m, 1H, H-7), 1.12 (s, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 175.3 (CO), 137.1 (=CH), 136.7, 128.6, 128.3, and 127.5 (Ph), 116.0 (=CH₂), 111.2 (C-5), 67.1 (C-8a), 64.8 and 63.5 (OCH₂), 55.1 (C-3), 44.3 (CH₂Ph), 41.0 (C-4), 39.5 (C-3a), 39.0 (C-6), 33.9 (3-CH₂), 30.3 (Me), 28.1 (C-8), 20.6 (C-7); HRMS (ESI-TOF) m/z [$M + H$]⁺ calcd for $\text{C}_{22}\text{H}_{30}\text{NO}_3$ 356.2220, found 356.2228.

(3*RS*,3*aSR*,8*aSR*)-1-Benzyl-3*a*-methyl-3-(3'-hydroxypropyl)-hexahydrocyclohepta[b]pyrrole-2,5(1*H*,3*H*)-dione Ethylene Acetal (**18**). A solution of **17** (3.61 g, 10.2 mmol) and a 9-BBN solution (0.5 M in THF, 40.6 mL, 20.3 mmol) was stirred for 5 h at room temperature. Then, at 0 °C, 2 M NaOH (40.5 mL) and H_2O_2 (46 mL) were added, and the reaction mixture was stirred at room temperature overnight. Water was added (150 mL), and the mixture was extracted with EtOAc (4 × 100 mL). The combined organics were dried, filtered, concentrated, and purified by chromatography (9.9:0.1 → 9.5:0.5 CH_2Cl_2 /MeOH) to give alcohol **18** (3.56 g, 94%) as a colorless waxy solid: IR (NaCl) 3406, 2869, 1673, 1434, 700 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.34–7.20 (m, 5H, Ph), 5.01 (d, J = 14.8 Hz, 1H, CH₂Ph), 3.92–3.83 (m, 5H, CH₂Ph and OCH₂), 3.77–3.72 and 3.69–3.63 (2m, 1H each, CH₂OH), 2.98 (dd, J = 10.8, 2.4 Hz, 1H, H-8a), 2.12–2.08 (m, 2H, H-4 and H-3), 1.94–1.57 (m, 9H, H-4, H-6, 1'-CH₂-3, H-7, 2'-CH₂-3, H-8), 1.55–1.45 (m, 1H, H-8), 1.40–1.33 (m, 1H, H-7), 1.10 (s, 3H, Me); $^{13}\text{C}\{^1\text{H}\}$ NMR (101

MHz, CDCl₃) δ 176.4 (C-2), 136.6, 128.6, 128.3, 127.5 (Ph), 111.2 (C-5), 67.1 (C-8a), 64.9 and 63.5 (OCH₂), 62.6 (CH₂OH), 54.4 (C-3), 44.3 (CH₂Ph), 40.5 (C-4), 39.7 (C-3a), 39.0 (C-6), 31.2 (2'-CH₂-3), 29.8 (Me), 28.2 (C-8), 26.5 (1'-CH₂-3), 20.8 (C-7); HRMS (ESI-TOF) m/z [M + H]⁺ calcd for C₂₂H₃₂NO₄ 374.2326, found 374.2329.

(3*RS*,3*aSR*,8*aSR*)-1-Benzyl-3*a*-methyl-3-(3'-methoxypropyl)-hexahydrocyclohepta[b]pyrrole-2,5(1*H*,3*H*)-dione Ethylene Acetal (**19**). To a solution of **18** (3.63 g, 9.72 mmol) in THF (150 mL) at 0 °C was added portionwise NaH (60% in mineral oil, 1.17 g, 29.2 mmol, 3 equiv). After the mixture had been stirred at this temperature for 30 min, iodomethane (1.8 mL, 29.2 mmol, 3 equiv) was added. The reaction mixture was stirred at room temperature overnight, the reaction quenched with NH₄Cl, and the mixture extracted with CH₂Cl₂ (4 × 100 mL). The combined organics were dried, filtered, concentrated, and purified by chromatography (9:0.1 → 9.5:0.5 CH₂Cl₂/MeOH) to provide protected alcohol **19** (3.3 g, 87%) as a yellowish waxy solid: IR (NaCl) 2933, 1680, 1448, 1118, 1074, 731, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.33–7.20 (m, 5H, Ph), 5.00 (d, J = 14.8 Hz, 1H, CH₂Ph), 3.90–3.83 (m, 4H, OCH₂ and CH₂Ph), 3.47–3.35 (m, 2H, CH₂OMe), 3.33 (s, 3H, OMe), 2.95 (dd, J = 11.0, 2.2 Hz, 1H, H-8a), 2.11 (d, J = 14.6, 1H, H-4), 1.94 (dd, J = 9.7, 5.4 Hz, 1H, H-3), 2.05–1.88 (m, 2H, 2'-CH₂-3 and H-8), 1.80–1.66 (m, 4H, 2'-CH₂-3, 1'-CH₂-3, H-6, and H-7), 1.64–1.59 (m, 1H, H-6), 1.59 (d, J = 14.6 Hz, 1H, H-4), 1.55–1.43 (m, 2H, 1'-CH₂-3 and H-8), 1.40–1.32 (m, 1H, H-7), 1.09 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 175.9 (C-2), 136.8, 128.6, 128.3, and 127.4 (Ph), 111.3 (C-5), 72.6 (CH₂OMe), 67.0 (C-8a), 64.9 and 63.4 (OCH₂), 58.5 (OMe), 54.9 (C-3), 44.2 (CH₂Ph), 40.7 (C-4), 39.4 (C-3a), 38.9 (C-6), 30.0 (Me), 28.5 (2'-CH₂-3), 28.1 (C-8), 26.7 (1'-CH₂-3), 20.9 (C-7); HRMS (ESI-TOF) m/z [M + H]⁺ calcd for C₂₃H₃₄NO₄ 388.2482, found 388.2475.

(3*RS*,3*aSR*,8*aSR*)-3-(3-Methoxypropyl)-3*a*-methyl-1-(2,2,2-trichloroacetyl)octahydrocyclohepta[b]pyrrol-5(1*H*)-one Ethylene Acetal (**21**). A suspension of LiAlH₄ (0.84 g, 22.1 mmol, 4 equiv) in THF (22 mL) was cooled to 0 °C, and then a solution of lactam **19** (2.15 g, 5.54 mmol) in THF (27 mL) was added dropwise. Then, the reaction mixture was heated to reflux and stirred for 4 h before the reaction was cautiously quenched with 15% NaOH. Water was added (20 mL), and the aqueous layer was extracted with CH₂Cl₂ (5 × 20 mL). The organic phase was dried, filtered, and concentrated under vacuum to afford a crude residue, which was purified by a chromatographic column (4:1 → 1:1 hexane/EtOAc), providing amine **20** (1.35 g, 66%) as a waxy solid: IR (NaCl) 2927, 1451, 1008, 701 cm⁻¹. To a solution of amine **20** (1.35 g, 3.61 mmol) in MeOH (42 mL) was added Pd/C (0.68 g, 50% wt.), and the reaction mixture was stirred under a H₂ atmosphere at rt overnight. Then, it was filtered through a Celite pad and concentrated to afford compound **21** (1.02 g, quantitative yield), which was used directly in the next step: IR (NaCl) 3425, 3421, 2929, 1694, 1455, 1112 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 3.39–3.85 (m, 3H, OCH₂), 3.80–3.75 (m, 1H, OCH₂), 3.36 (t, J = 6 Hz, 2H, CH₂OMe), 3.33 (s, 3H, OMe), 3.20 (dd, J = 10.8, 8.4 Hz, 1H, H-2), 3.00 (t, J = 4.4 Hz, 1H, H-8a), 2.65 (dd, J = 10.8, 9.8 Hz, 1H, H-2), 1.93 (d, J = 15.0 Hz, 1H, H-4), 1.95–1.85 (m, 2H, H-6 and H-8), 1.78–1.64 (m, 4H, H-3, H-6, H-8, and H-7), 1.58–1.48 (m, 4H, 3-CH₂-2', H-7, and 3-CH₂-1'), 1.45 (d, J = 15.0 Hz, 1H, H-4), 1.24–1.16 (m, 1H, 3-CH₂-1'), 1.14 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 112.6 (C-5), 72.8 (CH₂OMe), 67.7 (C-8a), 64.6 and 63.3 (OCH₂), 58.5 (OMe), 53.1 (C-3), 48.7 (C-2), 43.4 (C-3a), 39.5 (C-6), 37.3 (C-4), 31.2 (C-8), 28.9 (3-CH₂-2'), 25.6 (3-CH₂-1'), 23.9 (Me), 18.4 (C-7).


(3*RS*,3*aSR*,8*aSR*)-3-(3-Methoxypropyl)-3*a*-methyl-1-(2,2,2-trichloroacetyl)octahydrocyclohepta[b]pyrrol-5(1*H*)-one Ethylene Acetal (**22**). A solution of amine **21** (1.02 g, 3.53 mmol) in CH₂Cl₂ (11 mL) was cooled to 0 °C, and pyridine (0.6 mL, 7.41 mmol, 2.1 equiv) and trichloroacetyl chloride (0.6 mL, 5.29 mmol, 1.5 equiv) were added. The reaction mixture was stirred overnight; then water basified with 15% NaOH was added, and the aqueous layer was extracted with CH₂Cl₂ (4 × 20 mL). The combined organics were dried, filtered, and concentrated to afford a crude residue, which was

purified by chromatography (9:1 hexane/EtOAc), providing trichloroacetamide **22** (1.44 g, 93%): IR (NaCl) 2933, 1698, 1376, 1113, 700 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.28 (dd, J = 11.6, 7.2 Hz, 1H, H-2), 3.99 (dd, J = 10, 2.4 Hz, 1H, H-8a), 3.96–3.87 (m, 4H, OCH₂), 3.52 (dd, J = 11.6, 8 Hz, 1H, H-2), 3.39 (t, J = 6 Hz, 2H, CH₂OMe), 3.33 (s, 3H, OMe), 2.10–2.04 (m, 2H, H-4 and H-8), 1.86–1.75 (m, 2H, H-3 and H-6), 1.71–1.51 (m, 7H, H-4, H-6, 3-CH₂-2', H-8, 3-CH₂-1', and H-7), 1.53–1.44 (m, 1H, 3-CH₂-2'), 1.35–1.29 (m, 1H, 3-CH₂-1'), 1.26 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 156.3 (CO), 111.5 (C-5), 93.9 (CCl₃), 72.5 (CH₂OMe), 71.0 (C-8a), 64.8 and 63.6 (OCH₂), 58.7 (OMe), 52.5 (C-2), 51.6 (C-3), 42.5 (C-3a), 40.9 (C-4), 38.8 (C-6), 30.2 (Me), 29.3 (3-CH₂-2'), 28.1 (C-8), 26.1 (3-CH₂-1'), 20.0 (C-7); HRMS (ESI-TOF) m/z [M + H]⁺ calcd for C₁₈H₂₉Cl₃NO₄ 428.1157, found 428.1164.

(3*RS*,3*aSR*,8*aSR*)-3-(3-Methoxypropyl)-3*a*-methyl-1-(2,2,2-trichloroacetyl)octahydrocyclohepta[b]pyrrol-5(1*H*)-one (**23**). Chloroacetamide **22** (1.16 g, 2.71 mmol) was diluted in THF (20 mL), and a 10% HCl solution (40 mL) was added. After the mixture had been stirred at room temperature overnight, water (20 mL) was added, and the mixture was extracted with CH₂Cl₂ (4 × 25 mL). The combined organics were dried, filtered, and concentrated, and the obtained crude residue was purified by chromatography (9:1 → 4:1 hexane/EtOAc) to yield chloroacetamide **23** (0.94 g, 90%) as a colorless oil: IR (NaCl) 2934, 2870, 1703, 1679, 1453, 1389, 1116, 811, 699 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.37 (dd, J = 11.2, 6.8 Hz, 1H, H-2), 3.90 (dd, J = 7.0, 6.2 Hz, 1H, H-8a), 3.41–3.33 (m, 3H, H-2 and CH₂OMe), 3.34 (s, 3H, OMe), 2.73 (d, J = 11.4 Hz, 1H, H-4), 2.66–2.58 (m, 1H, H-8), 2.40 (bt, J = 6.0 Hz, 2H, H-6), 2.14 (d, J = 11.4 Hz, 1H, H-4), 1.87–1.52 (m, 7H, H-3, H-8, 2'-CH₂-3, H-7, 1'-CH₂-3), 1.36–1.27 (m, 1H, 1'-CH₂-3), 1.13 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 211.9 (C-5), 159.7 (CO), 93.7 (C), 72.4 (CH₂OMe), 71.1 (C-8a), 58.7 (OMe), 53.5 (C-2), 50.1 (C-3), 45.3 (C-6), 44.4 (C-4), 43.6 (C-3a), 28.9 (2'-CH₂-3), 25.7 (C-8), 25.1 (Me), 23.7 (1'-CH₂-3), 16.9 (C-7); HRMS (ESI-TOF) m/z [M + H]⁺ calcd for C₁₆H₂₅Cl₃NO₃ 384.0895, found 384.0904.

(3*RS*,3*aSR*,8*aSR*)-3-(3-Methoxypropyl)-3*a*-methyl-1-(2,2,2-trichloroacetyl)-2,3,3*a*,4,8,8*a*-hexahydrocyclohepta[b]pyrrol-5(1*H*)-one (**24**). A solution of trichloroacetamide **23** (0.36 g, 0.93 mmol), IBX (0.65 g, 2.33 mmol, 2.5 equiv), and *p*-TsOH (53 mg, 0.28 mmol, 0.4 equiv) in DMSO (9 mL) was heated at 70 °C overnight. Upon cooling, the mixture was portioned between EtOAc (20 mL) and water (20 mL), and the aqueous layer was extracted with EtOAc (5 × 10 mL). The combined organic layers were dried, filtered, and concentrated to afford the crude product, which was purified by flash column chromatography (1:0 → 9.5:0.5 CH₂Cl₂/MeOH), and enone **24** (0.21 g, 60%) was obtained along with traces of overoxidized product **24b**: IR (NaCl) 2931, 1700, 1075, 1115 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.64 (ddd, J = 11.2, 8.2, 4.6 Hz, 1H, H-7), 6.14 (dd, J = 11.2, 2.0 Hz, 1H, H-6), 4.31 (dd, J = 11.6, 7.2 Hz, 1H, H-2), 4.12 (d, J = 7.2 Hz, 1H, H-8a), 3.43–3.32 (m, 3H, CH₂OMe and H-8), 3.34 (s, 3H, OMe), 3.09 (t, J = 11.6 Hz, 1H, H-2), 2.74 (dddd, J = 16.4, 4.6, 2.2, 2.0 Hz, 1H, H-8), 2.68 and 2.53 (dd, J = 13.2 Hz, 1H each, H-4), 1.97–1.89 (m, 1H, H-3), 1.71–1.48 (m, 4H, 1'-CH₂-3 and 2'-CH₂-3), 1.22 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 200.7 (C-5), 158.6 (CO), 143.9 (C-7), 134.9 (C-6), 93.3 (C), 72.4 (CH₂OMe), 70.5 (C-8a), 58.7 (OMe), 54.2 (C-2), 49.5 (C-4), 49.1 (C-3), 44.8 (C-3a), 29.0 (2'-CH₂-3), 27.7 (C-8), 27.1 (C-8), 23.9 (1'-CH₂-3); HRMS (ESI-TOF) m/z [M + H]⁺ calcd for C₁₆H₂₃Cl₃NO₃ 382.0738, found 382.0739.

Overoxidized Compound **24b**.



IR (NaCl) 2927, 2868, 1702, 1677, 1459, 1390, 1116, 843 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 6.87 (ddd, J = 11.2, 9.0, 3.0 Hz, 1H, H-

7), 6.30 (dd, $J = 11.2, 3.2$ Hz, 1H, H-6), 4.47 (dd, $J = 11.8, 8.0$ Hz, 1H, H-2), 4.18 (d, $J = 6.8$ Hz, 1H, H-8a), 3.62 (ddd, $J = 17.2, 9.2, 7.2$ Hz, 1H, H-8), 3.45 (t, $J = 11.8$ Hz, 1H, H-2), 3.39–3.33 (m, 2H, CH₂OMe), 3.32 (s, 3H, OMe), 2.46 (dt, $J = 17.2, 2.8$ Hz, 1H, H-8), 2.24–2.15 (m, 1H, H-3), 1.69–1.51 (m, 3H, 2'-CH₂-3 and 1'-CH₂-3), 1.46–1.42 (m, 1H, 3-CH₂-1'), 1.39 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 206.6 (C-4), 196.6 (C-5), 159.1 (CO), 146.9 (C-7), 130.3 (C-6), 92.9 (C), 72.1 (CH₂OMe), 67.7 (C-8a), 58.7 (OMe), 58.6 (C-3a), 54.5 (C-2), 47.7 (C-3), 28.8 (2'-CH₂-3), 28.2 (C-8), 24.8 (1'-CH₂-3), 18.8 (Me).

(3*RS*,3*aSR*,7*RS*,8*aSR*)-3-(3-Methoxypropyl)-3*a*-methyloctahydro-5*H*-1,7-ethanocyclohepta[*b*]pyrrole-5,10-dione (**25**). A solution of trichloroacetamide **24** (0.21 g, 0.56 mmol) in benzene (19 mL) was heated to reflux. Then, a solution of AIBN (46 mg, 0.28 mmol, 0.5 equiv) and Bu₃SnH (0.6 mL, 2.24 mmol, 4 equiv) in benzene (4 mL) was added over 4 h via a syringe pump. The reaction mixture was stirred for an additional 1 h, cooled, and concentrated. The residue was purified by chromatography (1:0 → 9.9:0.1 CH₂Cl₂/MeOH) to obtain tricyclic compound **25** (110 mg, 72%): IR (NaCl) 2926, 2870, 1695, 1645, 1455, 1117 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 3.45–3.37 (m, 4H, 3-CH₂-3', H-2, and H-8a), 3.33 (s, 3H, OMe), 3.12 (dd, $J = 12.0, 10.0$ Hz, 1H, H-2), 2.64 (dd, $J = 13.0, 8.2$ Hz, 1H, H-6), 2.50 (m, 1H, H-7), 2.44–2.31 (m, 4H, H-6, H-4, and H-9), 2.25–2.21 (m, 3H, H-4 and H-8), 1.84 (ddd, $J = 20.0, 10.0, 1.8$ Hz, 1H, H-3), 1.67–1.62 (m, 2H, 2'-CH₂-3 and 1'-CH₂-3), 1.56–1.49 (m, 2H, 2'-CH₂-3 and 1'-CH₂-3), 1.06 (s, 3H, Me); ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 207.9 (C-5), 168.2 (C-10), 72.6 (3-CH₂-3), 64.8 (C-8a), 58.6 (OMe), 50.2 (C-6), 48.2 (C-2), 46.8 (C-3a), 46.7 (C-3), 45.1 (C-4), 39.7 (C-9), 28.6 (2'-CH₂-3), 26.1 (1'-CH₂-3), 25.9 (C-7), 25.3 (C-8), 24.3 (Me); HRMS (ESI-TOF) m/z [M + H]⁺ calcd for C₁₆H₂₆NO₃ 280.1907, found 280.1914.

■ ASSOCIATED CONTENT

Data Availability Statement

The data underlying this study are available in the published article and its [Supporting Information](#).

■ Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.joc.4c01090>.

Copies of ¹H and ¹³C NMR spectra of all reported compounds (PDF)

FAIR data, including the primary NMR FID files, for compounds **1–25** (ZIP)

■ AUTHOR INFORMATION

Corresponding Authors

Faïza Diaba – Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, 08028 Barcelona, Spain; orcid.org/0000-0001-9950-2470; Email: faiza.diaba@ub.edu

Josep Bonjoch – Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, 08028 Barcelona, Spain; orcid.org/0000-0002-5551-6720; Email: josep.bonjoch@ub.edu

Authors

Clàudia Marquès – Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, 08028 Barcelona, Spain; orcid.org/0000-0002-1981-4763

David González-Lizana – Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, 08028 Barcelona, Spain

Complete contact information is available at: <https://pubs.acs.org/10.1021/acs.joc.4c01090>

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support for this research was provided by Grant PID2022-139257NB-I00 funded by MICIU/AEI/10.13039/501100011033 (Spain) and FEDER, UE. Access funding provided via the agreement between Universitat de Barcelona and the American Chemical Society.

■ REFERENCES

- (1) (a) Guo, L.-D.; Chen, Y.; Xu, J. Total Synthesis of *Daphniphyllum* Alkaloids: From Bicycles to Diversified Caged Structures. *Acc. Chem. Res.* **2020**, *53*, 2726–2737. (b) Chattopadhyay, A. K.; Hanessian, S. Recent progress in the chemistry of *Daphniphyllum* alkaloids. *Chem. Rev.* **2017**, *117*, 4104–4146.
- (2) Kobayashi, J.; Inaba, Y.; Shiro, M.; Yoshida, N.; Morita, H. Daphniphyllins A–H, Novel Hexa- or Pentacyclic Alkaloids from two species of *Daphniphyllum*. *J. Am. Chem. Soc.* **2001**, *123*, 11402–11408.
- (3) Zhang, D.-D.; Xu, J.-B.; Fan, Y.-Y.; Gan, L.-S.; Zhang, H.; Yue, J.-M. Daphniphyllins A and B: Alkaloids Representing Two Unknown Carbon Skeletons from *Daphniphyllum longeracemosum*. *J. Org. Chem.* **2020**, *85*, 3742–3747.
- (4) Zhang, W.; Guo, Y.-W.; Krohn, K. Macropodumines A–C: Novel Pentacyclic Alkaloids with an unusual skeleton of Zwitterion Moiety from *Daphniphyllum macropodum* Miq. *Chem. - Eur. J.* **2006**, *12*, 5122–5127.
- (5) Zou, Y.-P.; Lai, Z.-L.; Zhang, M.-W.; Peng, J.; Ning, S.; Li, C.-C. Total Synthesis of (±)- and (–)-Daphniphyllin B. *J. Am. Chem. Soc.* **2023**, *145*, 10998–11004.
- (6) (a) Williams, D. R.; Mondal, P. K.; Bawel, S. A.; Nag, P. P. Stereocontrolled synthesis of the tricyclic ABC ring system of daphniphyllidin A. *Org. Lett.* **2014**, *16*, 1956–1959. (b) Li, J. L.; Shi, H. W.; Wang, Q.; Chai, Y. H.; Yang, J. Synthesis of the ABC tricyclic system of Daphniphyllidin A. *J. Org. Lett.* **2017**, *19*, 1497–1499. (c) Tu, J.; Clark, M. M.; Harmata, M. First synthesis of an ABCE ring substructure of daphniphyllidin A. *Org. Biomol. Chem.* **2022**, *20*, 6547–6549. (d) Tu, J.; Ripa, R. A.; Kelley, S. P.; Harmata, M. Intramolecular [4+3] Cycloadditions of Oxopyridinium Ions: Towards Daphniphyllidin A. *Chem. - Eur. J.* **2022**, *28*, No. e202200370.
- (7) The work reported here formed part of the Ph.D. thesis of Claudia Marques (Universitat de Barcelona) entitled “Azapolycyclic building blocks for the synthesis of *Daphniphyllum* alkaloids: approaches toward himalensine A and 2-deoxymacropodumine A”, which was defended on December 15, 2023. At the same time, a Note was published by the group of Xie and She.⁸
- (8) Duan, X.; Xu, H.; Shen, Y.; Liu, A.; He, F.; Hou, H.; Li, H.; Xie, X.; She, X. Synthesis of the 5–6-7 tricyclic core of daphniphyllidin-type alkaloids via a Tiffeneau-Demjanov ring enlargement strategy. *J. Org. Chem.* **2023**, *88*, 14842–14846.
- (9) Zhang, W.; Lu, M.; Ren, L.; Zhang, X.; Liu, S.; Ba, M.; Yang, P.; Li, A. Total synthesis of four classes of *Daphniphyllum* alkaloids. *J. Am. Chem. Soc.* **2023**, *145*, 26569–26579.
- (10) Amat, M.; Perez, M.; Minaglia, A. T.; Bosch, J. An enantioselective synthetic route to *cis*-2,4-disubstituted and 2,4-bridged piperidines. *J. Org. Chem.* **2008**, *73*, 6920–6923.
- (11) Wang, Y.-F.; Toh, K. K.; Ng, E. P. J.; Chiba, S. Mn(III)-mediated [3+3]-annulation of vinyl azides and cyclopropanols: a divergent synthesis of azaheterocycles. *J. Am. Chem. Soc.* **2011**, *133*, 6411–6421.
- (12) Fu, C.; Kelley, S. P.; Tu, J.; Harmata, M. Generation of the 7-azabicyclo[4.3.1]decane ring system via (4+3) cycloaddition of oxidopyridinium ions. *J. Org. Chem.* **2021**, *86*, 7028–7037.
- (13) Shoemaker, A. H.; Foker, E. A.; Uttaro, E. P.; Beitel, S. K.; Griffith, D. R. Synthesis of 7-azabicyclo[4.3.1]decane ring systems from tricarbonyl (tropone)iron via intramolecular Heck reactions. *Beilstein Org. Chem.* **2023**, *19*, 1615–1619.

- (14) (a) Liu, H.; Sun, C.; Lee, N.-K.; Henry, R. F.; Lee, D. New methylene homologation method for cyclic ketones. *Chem. - Eur. J.* **2012**, *18*, 11889–11893. (b) Candeias, N. R.; Paterna, R.; Gois, P. M. P. Homologation reaction of ketones with diazo compounds. *Chem. Rev.* **2016**, *116*, 2937–2981. (c) Krüger, S.; Gaich, T. Total syntheses of vellosimine, *N*-methylvellosimine, and 10-methoxyvellosimine and formal synthesis of 16-epinormacusine B through a [5+2] cycloaddition. *Eur. J. Org. Chem.* **2016**, *2016*, 4893–4899.
- (15) Coussanes, G.; Vila, X.; Diaba, F.; Bonjoch, J. Radical cyclization of trichloroacetamides: synthesis of lactams. *Synthesis* **2017**, *49*, 1481–1499.
- (16) Quirante, J.; Escolano, C.; Costejà, L.; Bonjoch, J. Cyclization of 1-(carbamoyl)dichloromethyl radicals upon activated alkenes. A new entry to 2-azabicyclo[3.3.1]nonanes. *Tetrahedron Lett.* **1997**, *38*, 6901–6904.
- (17) Wegge, T.; Schwarz, S.; Seitz, G. A new and efficient synthetic route to enantiopure (+)-anatoxin-a from (–) cocaine hydrochloride. *Tetrahedron: Asymmetry* **2000**, *11*, 1405–1410.
- (18) Liu, H.; Sun, C.; Lee, N.-K.; Henry, R. F.; Lee, D. New methylene homologation method for cyclic ketones. *Chem. - Eur. J.* **2012**, *18*, 11889–11893.
- (19) Rebmann, H.; Gerlinger, C. K.; Gaich, T. Gram-scale total synthesis of sarpagine alkaloids and non-natural derivatives. *Chem. - Eur. J.* **2019**, *25*, 2704–2707.
- (20) Marquès, C.; Diaba, F.; Gómez-Bengoa, E.; Bonjoch, J. Synthesis of the ABC ring of calyciphylline A-type alkaloids by stereocontrolled aldol cyclization: Formal synthesis of (±)-himalensine. *J. Org. Chem.* **2022**, *87*, 10516–10522.
- (21) For other syntheses of functionalized methylperhydrocyclohepta[b]pyrroles, see: (a) Dunn, T. B.; Ellis, J. M.; Kofink, C. C.; Manning, J. R.; Overman, L. E. Asymmetric construction of rings A-D of Daphniphyllidin-type alkaloids. *Org. Lett.* **2009**, *11*, 5658–5661. (b) Jacobsen, E. J.; Levin, J.; Overman, L. E. Synthesis applications of cationic aza-Cope rearrangements. Scope and mechanism of tandem cationic-aza-Cope rearrangement-Mannich cyclization reactions. Using a tandem cationic aza-Cope rearrangement-Mannich cyclization reaction. *J. Am. Chem. Soc.* **1988**, *110*, 4329–4336. (c) Belov, D. S.; Ratmanova, N. K.; Andreev, I. A.; Kurkin, A. V. Synthesis of bicyclic proline derivatives by the aza-Cope-Mannich reaction: formal synthesis of (±)-acetylaranotin. *Chem. - Eur. J.* **2015**, *21*, 4141–4147.
- (22) Coussanes, G.; Bonjoch, J. Synthesis of the tetracyclic ABCD ring domain of calyciphylline A-type alkaloids via reductive radical cyclizations. *Org. Lett.* **2017**, *19*, 878–881.
- (23) Jansana, S.; Coussanes, G.; Puig, J.; Diaba, F.; Bonjoch, J. Synthesis of azabicyclic building blocks for *Daphniphyllum* alkaloid intermediates featuring *N*-trichloroacetyl enamide 5-endo-trig radical cyclizations. *Helv. Chim. Acta* **2019**, *102*, No. e1900188.
- (24) Juo, W.-J.; Lee, T.-H.; Liu, W.-C.; Ko, S.; Chittimalla, S. K.; Rao, C. P.; Liao, C.-C. Facial selectivity in the nucleophilic additions of vinylmagnesium bromide to bicyclo[2.2.2]oct-5-en-2-one derivatives. *J. Org. Chem.* **2007**, *72*, 7992–8004.
- (25) (a) For recent methodologies for carbonyl desaturation reactions, see: Gnaim, S.; Vantourout, J. C.; Serpier, F.; Echeverria, P.-G.; Baran, P. S. Carbonyl desaturation: where does catalysis stand? *ACS Catal.* **2021**, *11*, 883–892. (b) Bradshaw, B.; Etxebarría-Jardí, G.; Bonjoch, J. Total synthesis of (–)-anominine. *J. Am. Chem. Soc.* **2010**, *132*, 5966–5967. (c) Nicolaou, K. C.; Montagnon, T.; Baran, P. S.; Zhong, Y.-L. Iodine(V) reagents in organic synthesis. part 4. o-iodoxybenzoic acid as a chemospecific tool for single electron transfer-based oxidation processes. *J. Am. Chem. Soc.* **2002**, *124*, 2245–2258.
- (26) Bonjoch, J.; Diaba, F. Radical reactions in alkaloid synthesis: A perspective from carbon radical precursors. *Eur. J. Org. Chem.* **2020**, *2020*, 5070–5100.
- (27) Quirante, J.; Escolano, C.; Diaba, F.; Bonjoch, J. Radical promoted cyclisations of trichloroacetamides with silyl enol ethers and enol acetates: the role of the hydride reagent [tris(trimethylsilyl)-silane vs. tributylstannane]. *J. Chem. Soc. Perkin Trans 1* **1999**, 1157–1162.
- (28) For another synthesis of morphan **5c**, see: Boger, D. L.; Patel, M.; Mullican, M. D. Synthetic analgesics: preparation of racemic 6,7-benzomorphans. *Tetrahedron Lett.* **1982**, *23*, 4559–4562.